Fludarabine for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated and Previously Treated Patients

Autotransplants should be offered early for Waldentrom macroglobulinenia (WM)

B Barlogie;K Chansky;A Hoering;J Crowley;M Dhodapkar International Workshop for Waldenstrom's Macroglobulinemia (IWWM-9) (October 5-8, 2016, Amsterdam, Netherlands), LBA, oral, invited talk, session 15

Long term survival in Waldenstrom macroglobulinemia - 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003 [PMID18931340; PMC2630265]

MV Dhodapkar;A Hoering;MA Gertz;SE Rivkin;Jackie Szymonifka;J Crowley;Bart Barlogie Blood 113(4)793-796

International prognostic scoring system for Waldenstrom's macroglobulinemia [PMID19196866]

P Morel;A Duhamel;P Gobbi;M Dimopoulos;MV Dhodapkar;J McCoy;JJ Crowley;E Ocio;R Garcia-Sanz;S Treon;V Leblond;R Kyle;B Barlogie;G Merlini Blood 113(18):4163-4170

Prognostic factors and response to fludarabine therapy in Waldenstrom's Macroglobulinemia: an update of a US Intergroup trial (SWOG S9003)

MV Dhodapkar;JL Jacobson;MA Gertz;JJ Crowley;B Barlogie Seminars in Oncology 30(2):220-225

Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States Intergroup trial (Southwest Oncology Group S9003)

MV Dhodapkar;JL Jacobson;MA Gertz;SE Rivkin;GD Roodman;JM Tuscano;M Shurafa;RA Kyle;JJ Crowley;B Barlogie Blood 98(1):41-48

Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with waldenstrom's macroglobulinemia (WM)

MV Dhodapkar;J Jacobson;M Gertz;SE Rivkin;GR Weiss;DR Gandara;RA Chapman;JJ Crowley;S Salmon;R Kyle;B Barlogie Blood 94(10)Suppl.1:705a(#3115)part_1_of_2

Phase II intergroup trial of fludarabine (FAMP) in Waldenstrom's macroglobulinemia (WM): Results of Southwest Oncology Group trial (SWOG 9003).

M Dhodapkar;J Jacobson;M Gertz;J Crowley;M Shurafa;S Salmon;R Kyle;B Barlogie Blood 90(10)Suppl.1:577a(#2571)